S14 Ep35: FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/37/d9/f9/37d9f9c6-c820-66f3-7a4b-459aefa0484a/mza_9223874801391949533.jpg/600x600bb.jpg

OncLive® On Air

500 episodes

3 days ago

Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.

Health & Fitness

Science

RSS

All content for OncLive® On Air is the property of OncLive® On Air and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.

Health & Fitness

Science

https://audioboom.com/i/43145188/s=1400x1400/el=1/rt=fill.jpg

S14 Ep35: FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

OncLive® On Air

15 minutes

3 weeks ago

S14 Ep35: FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.